David Alland

David Alland
Dr David Alland earned a bachelor’s degree in psychology from Columbia University, an MD from the Columbia College of Physicians and Surgeons and an MSc and DTM&H from the London School of Hygiene and Tropical Medicine. He is currently a Professor of Medicine, Associate Dean for Clinical Research, and the Director of the Center for Emerging Pathogens at Rutgers University, New Jersey Medical School.

The Alland laboratory concentrates on diverse aspects of M. tuberculosis molecular biology, epidemiology, and advanced molecular diagnostics, as well as deciphering how antibiotic resistance develops on both the cellular and epidemiological levels. The laboratory interests also include rapid diagnostics of infectious agents for biodefense, intracellular consequences of antibiotic treatment, and the diagnosis of drug resistance.

Over the years, David has been the principal investigator of multiple National Institutes of Health (NIH) grants relating to tuberculosis, rapid detection of sepsis, and biodefense. He served as the Scientific Director of the TB–Clinical Diagnostics Research Consortium (CDRC), and is a member of the Tuberculosis Transformative Science Group of the AIDS Clinical Trials Group Network. He has also reviewed numerous grants for the NIH, World Health Organization, Gates Foundation, and Wellcome Trust. He currently has over 114 peer reviewed articles on tuberculosis, and on sepsis diagnosis, including publications in The New England Journal of Medicine, The Lancet, Nature Medicine, Nature Genetics, Nature Chemical Biology, PNAS and other prestigious Journals.